New combination therapy for advanced-stage RCC

Affiliations

Comment

Peter Sidaway. Nat Rev Clin Oncol. 2023 Jun.

. 2023 Jun;20(6):353.

doi: 10.1038/s41571-023-00765-y.

No abstract available

Comment on

Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Choueiri TK, et al. Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31. Lancet Oncol. 2023. PMID: 37011650 Clinical Trial.

1. Choueiri, T. K. et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(23)00097-9 (2023) - DOI - PubMed